Inherited variation in pattern recognition receptors and cancer: Dangerous liaisons?

Cancer Management and Research

Volumn 4, Issue 1, 2012, Pages 31-38

  Kutikhin, Anton G ^a   Yuzhalin, Arseniy E ^a  

^a KEMEROVO STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

C type lectin receptors; Cancer; Gene polymorphisms; NOD like receptors; Pattern recognition receptors; Toll like receptors

Indexed keywords

C TYPE LECTIN RECEPTOR; LECTIN RECEPTOR; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

BLADDER CANCER; BREAST CANCER; CANCER GROWTH; CANCER RISK; COLORECTAL CANCER; DNA POLYMORPHISM; ENDOMETRIUM CANCER; ENZYME ACTIVITY; ESOPHAGUS CANCER; GALLBLADDER CANCER; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; KAPOSI SARCOMA; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; NASOPHARYNX CARCINOMA; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; TESTIS CANCER; UTERINE CERVIX CANCER;

EID: 84857772203     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S28688     Document Type: Review

References (78)

1. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34(5):637-650.
2. Elinav E, Strowig T, Henao-Mejia J, Flavell RA. Regulation of the antimicrobial response by NLR proteins. Immunity. 2011;34(5): 665-679.
3. Osorio F, Reis e Sousa C. Myeloid C-type lectin receptors in pathogen recognition and host defense. Immunity. 2011;34(5):651-664.
4. Loo YM, Gale M Jr. Immune signaling by RIG-I-like receptors. Immunity. 2011;34(5):680-692.
5. Chang ZL. Important aspects of Toll-like receptors, ligands and their signaling pathways. Inflamm Res. 2010;59(10):791-808.
6. Fukata M, Chen A, Klepper A, et al. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology. 2006;131(3):862-877.
7. Brown SL, Riehl TE, Walker MR, et al. Myd88-dependent positioning of Ptgs2-expressing stromal cells maintains colonic epithelial proliferation during injury. J Clin Invest. 2007;117(1):258-269.
8. Kim D, Kim MA, Cho IH, et al. A critical role of toll-like receptor 2 in nerve injury-induced spinal cord glial cell activation and pain hypersensitivity. J Biol Chem. 2007;282(20):14975-14983.
9. Rakoff-Nahoum S, Medzhitov R. Role of toll-like receptors in tissue repair and tumorigenesis. Biochemistry (Mosc). 2008;73(5):555-561.
10. Seya T, Akazawa T, Uehori J, Matsumoto M, Azuma I, Toyoshima K. Role of toll-like receptor and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res. 2003;23(6a):4369-4376.
11. Okamoto M, Sato M. Toll-like receptor signaling in anti-cancer immunity. J Med Invest. 2003;50(1-2):9-24.
12. Chang AH, Parsonnet J. Role of bacteria in oncogenesis. Clin Microbiol Rev. 2010;23(4):837-857.
13. de Martel C, Franceschi S. Infections and cancer: established associations and new hypotheses. Crit Rev Oncol Hematol. 2009;70(3):183-194.
14. Viala J, Chaput C, Boneca IG, et al. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol. 2004;5(11):1166-1174.
15. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ. Peptidoglycan-and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem. 1999;274(25):17406-17409.
16. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol. 1999;163(1):1-5.
17. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem. 1999;274(16):10689-10692.
18. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004; 303(5663):1526-1529.
19. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408(6813):740-745.
20. Ferwerda G, Girardin SE, Kullberg BJ, et al. NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathog. 2005;1(3):279-285.
21. Opitz B, Püschel A, Schmeck B, et al. Nucleotide-binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae. J Biol Chem. 2004;279(35):36426-36432.
22. Kim JG, Lee SJ, Kagnoff MF. Nod1 is an essential signal transducer in intestinal epithelial cells infected with bacteria that avoid recognition by toll-like receptors. Infect Immun. 2004;72(3):1487-1495.
23. Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem. 2003;278(11):8869-8872.
24. Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DK. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology. 2003;124(4): 993-1000.
25. Sterka D Jr, Marriott I. Characterization of nucleotide-binding oligomerization domain (NOD) protein expression in primary murine microglia. J Neuroimmunol. 2006;179(1-2):65-75.
26. Welter-Stahl L, Ojcius DM, Viala J, et al. Stimulation of the cytosolic receptor for peptidoglycan, Nod1, by infection with Chlamydia trachomatis or Chlamydia muridarum. Cell Microbiol. 2006;8(6): 1047-1057.
27. Zilbauer M, Dorrell N, Elmi A, et al. A major role for intestinal epithelial nucleotide oligomerization domain 1 (NOD1) in eliciting host bactericidal immune responses to Campylobacter jejuni. Cell Microbiol. 2007;9(10):2404-2416.
28. Tsan MF. Toll-like receptors, inflammation, and cancer. Semin Cancer Biol. 2006;16(1):32-37.
29. Killeen SD, Wang JH, Andrews EJ, Redmond HP. Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword? Br J Cancer. 2006;95(3):247-252.
30. Chen R, Alvero AB, Silasi DA, Mor G. Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol. 2007;57(2):93-107.
31. Kinlen L. Infections and immune factors in cancer: the role of epidemiology. Oncogene. 2004;23(38):6341-6348.
32. Lamba V, Lamba J, Yasuda K, et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther. 2003;307(3):906-922.
33. Tierney MJ, Medcalf RL. Plasminogen activator inhibitor type 2 contains mRNA instability elements within exon 4 of the coding region. Sequence homology to coding region instability determinants in other mRNAs. J Biol Chem. 2001;276(17):13675-13684.
34. Thomas KH, Meyn P, Suttorp N. Single nucleotide polymorphism in 55-flanking region reduces transcription of surfactant protein B gene in H441 cells. Am J Physiol Lung Cell Mol Physiol. 2006;291(3): L386-L390.
35. Zysow BR, Lindahl GE, Wade DP, Knight BL, Lawn RM. C/T polymorphism in the 5CCuntranslated region of the apolipoprotein(a) gene introduces an upstream ATG and reduces in vitro translation. Arterioscler Thromb Vasc Biol. 1995;15(1):58-64.
36. Bell JK, Mullen GE, Leifer CA, Mazzoni A, Davies DR, Segal DM. Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol. 2003;24(10):528-533.
37. Johnson CM, Lyle EA, Omueti KO, et al. Cutting edge: a common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J Immunol. 2007;178(12): 7520-7524.
38. Eslick GD. Infectious causes of esophageal cancer. Infect Dis Clin North Am. 2010;24(4):845-852.
39. Fukata M, Abreu MT. Role of Toll-like receptors in gastrointestinal malignancies. Oncogene. 2008;27(2):234-243.
40. Angeletti S, Galluzzo S, Santini D, et al. NOD2/CARD15 polymorphisms impair innate immunity and increase susceptibility to gastric cancer in an Italian population. Hum Immunol. 2009;70(9):729-732.
41. Lecuit M, Abachin E, Martin A, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med. 2004;350(3):239-248.
42. Uronis JM, Mühlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One. 2009;4(6):e6026.
43. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol. 2010;10(2):131-144.
44. Freire P, Portela F, Donato MM, et al. CARD15 mutations and colorectal cancer in a South European country. Int J Colorectal Dis. 2010; 25(10):1211-1219.
45. Machida K. TLRs, alcohol, HCV, and tumorigenesis. Gastroenterol Res Pract. 2010;2010:518674.
46. Maeda S. NF-4B, JNK, and TLR Signaling pathways in hepatocarcinogenesis. Gastroenterol Res Pract. 2010;2010:367694.
47. Srivastava K, Srivastava A, Kumar A, Mittal B. Significant association between toll-like receptor gene polymorphisms and gallbladder cancer. Liver Int. 2010;30(7):1067-1072.
48. Del Pozo JL. Primers on molecular pathways: lipopolysaccharide signaling-potential role in pancreatitis and pancreatic cancer. Pancreatology. 2010;10(2-3):114-118.
49. Ashton KA, Proietto A, Otton G, et al. Toll-like receptor (TLR) and nucleosome-binding oligomerization domain (NOD) gene polymorphisms and endometrial cancer risk. BMC Cancer. 2010;10:382.
50. Pandey S, Mittal RD, Srivastava M, et al. Impact of Toll-like receptors [TLR] 2 ([196 to 1174 del) and TLR 4 (Asp299Gly, Thr399Ile) in cervical cancer susceptibility in North Indian women. Gynecol Oncol. 2009;114(3):501-505.
51. Zhou M, McFarland-Mancini MM, Funk HM, Husseinzadeh N, Mounajjed T, Drew AF. Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunol Immunother. 2009;58(9): 1375-1385.
52. Lubiński J, Huzarski T, Kurzawski G, et al. The 3020insC allele of NOD2 predisposes to cancers of multiple organs. Hered Cancer Clin Pract. 2005;3(2):59-63.
53. Petricevic B, Vrbanec D, Jakic-Razumovic J, et al. Expression of Toll-like receptor 4 and beta 1 integrin in breast cancer. Med Oncol. March 13, 2011. Epub Mar 13.
54. Vidas Z. Polymorphisms in Toll-like receptor genes-implications for prostate cancer development. Coll Antropol. 2010;34(2):779-783.
55. Holl K, Surcel HM, Koskela P, et al. Maternal Epstein-Barr virus and cytomegalovirus infections and risk of testicular cancer in the offspring: a nested case-control study. APMIS. 2008;116(9):816-822.
56. Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, Wang JM. Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol. 2007;7(10):1271-1285.
57. Wei JA, Zeng X, Han L, Huang Y. Establishment of a bladder cancer cell line with toll-like receptor 2 gene knockdown and identification of its biological characteristics. Nan Fang Yi Ke Da Xue Xue Bao. 2010;30(8):1797-1800. Chinese.
58. Song C, Chen LZ, Zhang RH, Yu XJ, Zeng YX. Functional variant in the 33-untranslated region of Toll-like receptor 4 is associated with nasopharyngeal carcinoma risk. Cancer Biol Ther. 2006;5(10):1285-1291.
59. Pinto A, Morello S, Sorrentino R. Lung cancer and Toll-like receptors. Cancer Immunol Immunother. 2011;60(9):1211-1220.
60. Wolska A, Lech-Maranda E, Robak T. Toll-like receptors and their role in hematologic malignancies. Curr Mol Med. 2009;9(3):324-335.
61. Türe-Ozdemir F, Gazouli M, Tzivras M, et al. Association of polymorphisms of NOD2, TLR4 and CD14 genes with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. Anticancer Res. 2008;28(6A):3697-3700.
62. Lagos D, Vart RJ, Gratrix F, et al. Toll-like receptor 4 mediates innate immunity to Kaposi sarcoma herpesvirus. Cell Host Microbe. 2008;4(5):470-483.
63. Kutikhin AG. Impact of Toll-like receptor 4 polymorphisms on risk of cancer. Hum Immunol. 2011;72(2):193-206.
64. Kutikhin AG. Role of NOD1/CARD4 and NOD2/CARD15 gene polymorphisms in cancer etiology. Hum Immunol. 2011;72(10):955-968.
65. Kutikhin AG. Association of polymorphisms in TLR genes and in genes of the Toll-like receptor signaling pathway with cancer risk. Hum Immunol. 2011;72(11):1095-1116.
66. Tanne A, Neyrolles O. C-type lectins in immunity to Mycobacterium tuberculosis. Front Biosci (Schol Ed). 2011;3:1147-1164.
67. Park JY, Choi HJ, Prabagar MG, et al. The C-type lectin CD209b is expressed on microglia and it mediates the uptake of capsular polysaccharides of Streptococcus pneumoniae. Neurosci Lett. 2009; 450(3):246-251.
68. Ofek I, Crouch E, Keisari Y. The role of C-type lectins in the innate immunity against pulmonary pathogens. Adv Exp Med Biol. 2000;479: 27-36.
69. Hijazi K, Wang Y, Scala C, et al. DC-SIGN increases the affinity of HIV-1 envelope glycoprotein interaction with CD4. PLoS One. 2011;6(12):e28307.
70. Castanier C, Garcin D, Vazquez A, Arnoult D. Mitochondrial dynamics regulate the RIG-I-like receptor antiviral pathway. EMBO Rep. 2010; 11(2):133-138.
71. Ferwerda G, Netea MG, Joosten LA, van der Meer JW, Romani L, Kullberg BJ. The role of toll-like receptors and C-type lectins for vaccination against Candida albicans. Vaccine. 2010;28(3):614-622.
72. Mansour MK, Latz E, Levitz SM. Cryptococcus neoformans glycoantigens are captured by multiple lectin receptors and presented by dendritic cells. J Immunol. 2006;176(5):3053-3061.
73. Saijo S, Iwakura Y. Dectin-1 and Dectin-2 in innate immunity against fungi. Int Immunol. 2011;23(8):467-472.
74. Brummer E, Stevens DA. Collectins and fungal pathogens: roles of surfactant proteins and mannose binding lectin in host resistance. Med Mycol. 2010;48(1):16-28.
75. van Stijn CM, Meyer S, van den Broek M, et al. Schistosoma mansoni worm glycolipids induce an inflammatory phenotype in human dendritic cells by cooperation of TLR4 and DC-SIGN. Mol Immunol. 2010;47(7-8):1544-1552.
76. Cobbs CS, Soroceanu L, Denham S, Zhang W, Kraus MH. Modulation of oncogenic phenotype in human glioma cells by cytomegalovirus IE1-mediated mitogenicity. Cancer Res. 2008;68(3):724-730.
77. Hooper SJ, Wilson MJ, Crean SJ. Exploring the link between microorganisms and oral cancer: a systematic review of the literature. Head Neck. 2009;31(9):1228-1239.
78. Samaras V, Rafailidis PI, Mourtzoukou EG, Peppas G, Falagas ME. Chronic bacterial and parasitic infections and cancer: a review. J Infect Dev Ctries. 2010;4(5):267-281.